PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 22, 2024Frontiers in Medicine45 citationsOpen Access

Artificial intelligence in drug repurposing for rare diseases: a mini-review

View Full Paper
LCLucas CortialVMVincent MonteroSTSébastien Tourlet

Key Points

Key points are not available for this paper at this time.

Abstract

Drug repurposing, the process of identifying new uses for existing drugs beyond their original indications, offers significant advantages in terms of reduced development time and costs, particularly in addressing unmet medical needs in rare diseases. Artificial intelligence (AI) has emerged as a transformative force in healthcare, and by leveraging AI technologies, researchers aim to overcome some of the challenges associated with rare diseases. This review presents concrete case studies, as well as pre-existing platforms, initiatives, and companies that demonstrate the application of AI for drug repurposing in rare diseases. Despite representing a modest part of the literature compared to other diseases such as COVID-19 or cancer, the growing interest, and investment in AI for drug repurposing in rare diseases underscore its potential to accelerate treatment availability for patients with unmet medical needs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cortial et al. (2024) studied this question.

synapsesocial.com/papers/68e68e6fb6db6435876152d6https://doi.org/10.3389/fmed.2024.1404338
Ask AI
Helpful
Bookmark
Share
View Full Paper